Williams Jones & Associates LLC grew its position in shares of Galapagos NV (NASDAQ:GLPG) by 2.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 91,317 shares of the biotechnology company’s stock after purchasing an additional 2,535 shares during the quarter. Williams Jones & Associates LLC’s holdings in Galapagos NV were worth $6,988,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Federated Investors Inc. PA grew its holdings in shares of Galapagos NV by 36.8% during the second quarter. Federated Investors Inc. PA now owns 1,364,600 shares of the biotechnology company’s stock worth $104,419,000 after purchasing an additional 366,800 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Galapagos NV by 49.5% in the second quarter. Renaissance Technologies LLC now owns 465,300 shares of the biotechnology company’s stock valued at $35,605,000 after buying an additional 154,100 shares during the period. Wellington Management Group LLP increased its stake in shares of Galapagos NV by 9.5% in the first quarter. Wellington Management Group LLP now owns 458,088 shares of the biotechnology company’s stock valued at $39,483,000 after buying an additional 39,729 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Galapagos NV by 0.6% in the second quarter. Goldman Sachs Group Inc. now owns 202,173 shares of the biotechnology company’s stock valued at $15,471,000 after buying an additional 1,235 shares during the period. Finally, Clough Capital Partners L P increased its stake in shares of Galapagos NV by 336.1% in the first quarter. Clough Capital Partners L P now owns 74,870 shares of the biotechnology company’s stock valued at $6,453,000 after buying an additional 57,700 shares during the period. 23.62% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Galapagos NV (NASDAQ GLPG) traded up 0.25% during mid-day trading on Tuesday, reaching $103.01. The company had a trading volume of 45,177 shares. Galapagos NV has a 12-month low of $57.16 and a 12-month high of $103.54.

A number of brokerages recently issued reports on GLPG. Royal Bank Of Canada initiated coverage on shares of Galapagos NV in a report on Thursday, September 14th. They issued a “sector perform” rating and a $98.00 price objective for the company. Stifel Nicolaus boosted their target price on shares of Galapagos NV from $101.00 to $120.00 and gave the stock a “buy” rating in a report on Friday, September 15th. Zacks Investment Research cut shares of Galapagos NV from a “hold” rating to a “sell” rating in a research report on Monday. BidaskClub upgraded shares of Galapagos NV from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Finally, BTIG Research restated a “buy” rating and issued a $98.00 price target on shares of Galapagos NV in a research report on Tuesday, June 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $103.71.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/10/03/williams-jones-associates-llc-purchases-2535-shares-of-galapagos-nv-glpg.html.

Galapagos NV Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Institutional Ownership by Quarter for Galapagos NV (NASDAQ:GLPG)

Receive News & Stock Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related stocks with our FREE daily email newsletter.